"10.1371_journal.pone.0135278","plos one","2015-08-27T00:00:00Z","Christopher Ullman; Pascale Mathonet; Arkadiusz Oleksy; Agata Diamandakis; Licia Tomei; Anna Demartis; Chiara Nardi; Sonia Sambucini; Antonino Missineo; Karen Alt; Christoph E Hagemeyer; Matt Harris; Amos Hedt; Roland Weis; Kurt R Gehlsen","Isogenica, Ltd. Cambridge, United Kingdom; IRBM Science Park, Rome, Italy; Vascular Biotechnology, Baker IDI, Melbourne, Australia; Clarity Pharmaceuticals, Ltd. Sydney, Australia; VTU Technology, Grambach, Austria; Research Corporation Technologies, Inc. Tucson, Arizona, United States of America","Conceived and designed the experiments: KRG CU LT MH. Performed the experiments: PM AO A. Demartis A. Diamandakis CN SS AM KA CH AH RW. Analyzed the data: KRG CU PM AO LT A. Demartis CH MH. Contributed reagents/materials/analysis tools: CU PM LT A. Demartis AH RW. Wrote the paper: KRG CU PM A. Demartis KA CH MH RW.","The authors have the following interests. This study was funded and sponsored by Research Corporation Technologies, Inc., the employer of Kurt R. Gehlsen. Christopher Ullman, Pascale Mathonet, Arkadiusz Oleksy and Agata Diamandakis are employed by Isogenica, Ltd., Licia Tomei, Anna Demartis, Chiara Nardi, Sonia Sambucini and Antonino Missineo by IRBM Science Park, Karen Alt and Christoph E. Hagemeyer by Baker IDI, Matt Harris and Amos Hedt by Clarity Pharmaceuticals, Ltd. and Roland Weis by VTU Technology. Research Corporation Technologies, Inc. owns certain patents and patents applications covering the Abdurins and the EphA2 binder, however, there are no products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","08","Christopher Ullman","CU",15,TRUE,4,3,6,4,TRUE,TRUE,TRUE,4,"7;8;11;14",TRUE
